The Enterprise Value as of September 2024 (TTM) for Innoviva, Inc. (INVA) is 1.46B

According to Innoviva, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 1.46B. This represents a change of 19.84% compared to the average of 1.22B of the last 4 quarters.

Innoviva, Inc. (INVA) Historical Enterprise Value (quarterly & annually)

How has INVA Enterprise Value performed in the past?

The mean historical Enterprise Value of Innoviva, Inc. over the last ten years is 1.62B. The current 1.46B Enterprise Value has changed 8.94% with respect to the historical average. Over the past ten years (40 quarters), INVA's Enterprise Value was at its highest in in the June 2015 quarter at 2.57B. The Enterprise Value was at its lowest in in the September 2020 quarter at 963.35M.

Innoviva, Inc. (INVA) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Innoviva, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Innoviva, Inc. (INVA) Average Enterprise Value

How has INVA Enterprise Value performed in the past?

The current Enterprise Value of Innoviva, Inc. (INVA) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages

Innoviva, Inc. (INVA) Enterprise Value vs. Peers

How is INVA’s Enterprise Value compared to its peers?

Innoviva, Inc.’s Enterprise Value is greater than eFFECTOR Therapeutics, Inc. (3.85M), greater than Protalix BioTherapeutics, Inc. (87.33M), greater than PDS Biotechnology Corporation (84.84M), greater than aTyr Pharma, Inc. (138.44M), greater than Elevation Oncology, Inc. (6.92M), greater than Day One Biopharmaceuticals, Inc. (1.02B), less than Mirati Therapeutics, Inc. (3.91B), greater than Amylyx Pharmaceuticals, Inc. (124.22M), greater than Terns Pharmaceuticals, Inc. (615.29M), less than Apellis Pharmaceuticals, Inc. (4.59B), greater than X4 Pharmaceuticals, Inc. (50.24M), greater than Inozyme Pharma, Inc. (394.08M), greater than HOOKIPA Pharma Inc. (86.58M), greater than Acumen Pharmaceuticals, Inc. (115.26M), less than Amicus Therapeutics, Inc. (3.50B), less than Incyte Corporation (11.92B), less than Denali Therapeutics Inc. (4.42B), less than argenx SE (30.67B), less than Harmony Biosciences Holdings, Inc. (2.12B),

Build a custom stock screener for Innoviva, Inc. (INVA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Innoviva, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Innoviva, Inc. (INVA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Innoviva, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.